Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (Nasdaq: XOMA) is a biotechnology royalty aggregator that regularly reports on transactions, partner developments, and portfolio evolution. News about XOMA Royalty often centers on its acquisition of royalty and milestone interests in therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies, as well as on corporate events that affect its capital structure and governance.
Recent announcements highlight XOMA Royalty’s completion of acquisitions of companies such as HilleVax, LAVA Therapeutics, Mural Oncology, and Turnstone Biologics, which add partnered programs and associated economic interests to its portfolio. The company also issues updates on strategic royalty-sharing transactions, including amendments to its collaboration with Takeda related to mezagitamab and exposure to a basket of development-stage assets in Takeda’s externalized assets portfolio.
Investors following XOMA Royalty news will see regular disclosures on quarterly and year-to-date financial results, including royalty and milestone receipts from commercial assets like VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, and DSUVIA. The company’s releases also summarize key clinical and regulatory milestones reported by its partners, since these events can influence the timing and magnitude of potential royalty and milestone payments.
Additional news items cover preferred stock dividends on the company’s Series A and Series B Cumulative Perpetual Preferred Stock, at-the-market offerings of common and preferred securities, and leadership changes such as transitions in the Chief Financial Officer role. For investors and observers, the XOMA Royalty news feed provides a consolidated view of business development activity, partner pipeline progress, financing decisions, and governance updates that shape the company’s royalty and milestone portfolio over time.
XOMA Corporation (NASDAQ: XOMA) has appointed Heather L. Franklin, President and CEO of Blaze Bioscience, to its Board of Directors. With over 20 years in biotechnology, Franklin brings extensive experience in corporate development and strategy. She is recognized for negotiating significant deals, including a notable $1.1 billion collaboration with Bristol Myers Squibb. XOMA aims to enhance its royalty aggregator model by leveraging Franklin’s expertise in licensing and transactions to grow its portfolio of royalty assets.
XOMA Corporation announced its Q2 2021 financial results, reporting total revenues of $0.9 million, up from $0.4 million in Q2 2020, driven by a $0.5 million milestone from Janssen. Operating cash at quarter-end was $78.9 million, with no outstanding debt. The company raised $40 million through a preferred stock offering. Noteworthy developments include Orphan Drug Designation for NIS793 in pancreatic cancer and Rare Pediatric Disease Designation for DAY101. Despite a net loss of $2.2 million, XOMA's strong balance sheet supports future growth.
XOMA Corporation (NASDAQ: XOMA) has announced that NIS793, an investigational antibody targeting Transforming Growth Factor Beta (TGFβ), has received Orphan Drug Designation from the FDA for pancreatic cancer treatment. This designation provides various benefits to encourage drug development for rare diseases. Upon regulatory approval of NIS793, XOMA could earn up to $445 million through milestone payments and receive tiered royalties on net product sales. However, efficacy and safety of NIS793 have not yet been established, and commercialization is not guaranteed.
XOMA Corporation has acquired a royalty interest in Checkmate Pharmaceuticals’ therapy vidutolimod for $7 million, with potential sales milestones. Vidutolimod, a Toll-like receptor 9 agonist, aims to enhance the immune response against tumors, particularly in melanoma patients. The FDA has granted Fast Track and Orphan Drug designations for this treatment. XOMA stands to gain additional pre-commercial milestone payments of up to $25 million, positioned to benefit from future sales as Checkmate conducts multiple clinical studies to advance vidutolimod.
XOMA Corporation announced cash dividends for its preferred stockholders. Holders of 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.539 per share, while holders of 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive $0.55833 per depositary share. The dividends are scheduled for payment on July 15, 2021, to shareholders of record as of July 2, 2021. XOMA also operates as a biotechnology royalty aggregator, acquiring potential future economics associated with drug candidates that have been licensed to other pharmaceutical firms.
XOMA Corporation (Nasdaq: XOMA) announced its licensees will present at the 2021 ASCO Annual Meeting from June 4-8. CEO Jim Neal expressed excitement over Novartis and AVEO's advancements with drug candidates NIS793 and ficlatuzumab, respectively, which are moving towards Phase 3 clinical programs. The presentations will showcase their investigational compounds, with efficacy and safety still unproven. Investors should note that there is no guarantee these drugs will reach commercial availability.
XOMA reported a net loss of $7.4 million for Q1 2021, compared to $4.8 million in Q1 2020. The company's cash position improved to over $100 million following a $40 million Series B offering. As of March 31, XOMA held $67.8 million in cash, down from $84.2 million at the end of 2020. Total revenues decreased to $0.4 million from $0.8 million year-over-year. XOMA's portfolio now includes over 70 drug candidates, with recent acquisitions enhancing its pipeline. The board approved its first quarterly dividend payment for XOMAP, reflecting a strong financial posture amid an expanding asset base.
XOMA Corporation has secured a $0.5 million milestone payment from Janssen Biotech for the first patient dosed in a Phase 3 clinical trial of a biologic asset. This marks the second molecule to reach Phase 3 since XOMA shifted to a biotech royalty aggregator model in 2017. The company anticipates further milestone payments and royalties upon successful marketing approval and commercialization of the asset. With a portfolio of advancements, XOMA is positioned to potentially enhance shareholder value through its partnered programs.
XOMA Corporation (Nasdaq: XOMA) has expanded its portfolio of potential future milestone and royalty assets by adding three Affimed N.V. innate cell engager (ICE®) programs. The additions include AFM13 and AFM24, both designed to harness the innate immune system against cancer. XOMA is eligible for undisclosed payments on future sales and milestone payments upon marketing approvals of these molecules. CEO Jim Neal expressed excitement over the maturation of legacy technology agreements into potential revenue-generating assets, enhancing value for shareholders.
XOMA Corporation (Nasdaq: XOMA) announced the closing of its public offering of 1,600,000 depositary shares, representing a 1/1000th interest in its 8.375% Series B Cumulative Perpetual Preferred Stock. The offering raised gross proceeds of $40 million, netting approximately $38 million after fees. The funds will support a segregated dividend account and general corporate purposes, including future acquisitions related to drug development. Shares will trade on Nasdaq under the symbol 'XOMAO' soon.